Royalty Pharma Sub-Manager
Royalty Pharma Sub-Manager reported 4 stocks worth $242M in its 13F filing for Q2 2026, filed Aug 21, 2026. Its largest holdings are CYTK (34.5%), ZBIO (25.1%) and KLRA (22.4%). Compared with Q1 2026, the fund opened new positions in KLRA and sold out of BCRX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  CYTK Cytokinetics Inc | $83.5M | 34.5% | 980K | No change | 3 of 3 | |
| 2 |  ZBIO Zenas Biopharma Inc | $60.6M | 25.1% | 2.4M | No change | 3 of 3 | |
| 3 |  KLRA Kailera Therapeutics Inc | $54.1M | 22.4% | 2.5M | New position | 1 of 3 | |
| 4 |  BHVN Biohaven Ltd | $43.7M | 18.1% | 2.9M | No change | 3 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 BCRX Biocryst Pharmaceuticals Inc | $36.6M | 3.8M |
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 21, 2026 | 13F-HR/A Amendment | Q2 2026 | SEC filing ↗ |
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Includes an amendment, which can add positions the fund kept confidential at first, or replace the original report.
Other superinvestors
All hedge fund holdings →Royalty Pharma Sub-Manager 13F FAQ
What does Royalty Pharma Sub-Manager own?
Royalty Pharma Sub-Manager reported 4 stocks worth $242M in its 13F filing for Q2 2026, filed Aug 21, 2026. Its largest holdings are CYTK (34.5%), ZBIO (25.1%) and KLRA (22.4%). The table above lists every position in the filing (the top 10 without an account).
What did Royalty Pharma Sub-Manager buy and sell in Q2 2026?
Compared with Q1 2026: 1 new positions, 0 added to, 0 trimmed and 1 sold out. New positions include KLRA. It sold all of BCRX.
When will Royalty Pharma Sub-Manager file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Royalty Pharma Sub-Manager's portfolio worth?
The Q2 2026 filing reports $242M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.